Officer Dennis Mulroy Files to Sell Additional $835K in Stock, Continuing Recent Sales Trend
ANAB has more than doubled off its 52-week low of $11.402.
Summary
An officer at AnaptysBio has filed to sell an additional $834,903 in company stock, extending a recent trend of significant insider sales.
Key Events · Ownership and Investor Activity · ANAB
-
Officer Files to Sell Additional Shares
Dennis Mulroy, an officer, has filed a Form 144 indicating intent to sell 15,000 shares of common stock, valued at approximately $834,903.
-
Continuation of Significant Sales Trend
This proposed sale adds to a pattern of significant insider selling, with the same officer having already sold 75,731 shares for gross proceeds of over $4.5 million in the past three months. This is part of an ongoing pattern of Form 144 filings by the company's insiders.
-
Context of Recent Corporate Actions
The filing follows the company's recent completion of its biopharma spin-off into First Tracks Biotherapeutics and the announcement of a new $100 million share repurchase program.
Analysis · ANAB · Life Sciences
This Form 144 indicates an officer's intent to sell an additional $834,903 worth of shares. This follows a pattern of significant sales by the same officer, Dennis Mulroy, who has already sold over $4.5 million in stock in the past three months. The ongoing distribution by a key insider could be interpreted negatively by investors, especially given the company's recent spin-off and share repurchase program.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $55.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $11.40 to $72.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.